Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia.

Leukemia & lymphoma - 1 May 2023

Mustafa Ali Moaath K, Williams Matthew T, Corley Elizabeth M, AlKaabba Fahad, Niyongere Sandrine

Abstract excerpt

The prognostic significance of RAS mutations in AML is poorly understood. In this ambispective cohort study of 239 newly-diagnosed AML patients at the University of Maryland, we assessed the median overall survival (mOS) and median event-free survival (mEFS) in RAS wild-type (WT) AML (n = 196), KRAS-mutated AML (n = 11), NRAS-mutated AML (n = 25), and KRAS/NRAS-mutated AML (n = 7). We used propensity score to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37042657
DOI: 10.1080/10428194.2023.2190432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia.PMID 37042657Read ↗

RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.Semantic proximity Read ↗

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.Semantic proximity Read ↗

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia.Semantic proximity Read ↗

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Semantic proximity Read ↗

RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.Semantic proximity Read ↗

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.Semantic proximity Read ↗

Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid LeukemiaSemantic proximity Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaSemantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.